End-to-end Phase I and IIa Clinical StudiesDrug development is a logical step-wise process. In the early phase of drug development, the overall objective of phase I studies is to obtain tolerability, pharmacology and pharmacokinetic data to predict the dose regimen for phase II studies as well as to establish the drug safety profile. For phase I and IIa clinical studies, Business & Decision Life Sciences provides a cost-effective end-to-end solution, built around the clinical services of a 30-bed phase I and IIa unit. Additional supporting services include protocol writing, operational management and monitoring, clinical data management, statistical and pharmacokinetic analysis, as well as report writing.
Protocol DevelopmentBusiness & Decision Life Sciences supports the protocol development with clinical, medical writing and statistical services. This includes the design of the study, the formulation of clinical endpoints, sample size and power calculations, protocol writing, etc... Clinical and Operational ManagementThe operational project management services include site selection, initiation and training, ethical committee submissions, study document writing and review, study budgeting and follow-up.
Clinical Data ManagementBusiness & Decision Life Sciences develops the case report form (CRF), builds the database, and subsequently collects and reviews the clinical data. The data are cleaned using extensive data consistency checks and listings, and are delivered in CDISC format. AnalysisThe biostatistics department creates the statistical analysis plan (SAP), produces the analysis datasets, performs the statistical analysis, as well as the compartmental and non-compartmental pharmacokinetic analyses. ReportingReporting services include the creation of the statistical report, the clinical study report, writing of scientific publications and the investigator brochure. |
||
© 2011
All rights reserved
Accessibility | legal notice | contact | sitemap |